This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

GlaxoSmithKline PLC (GSK)

NYSE: Health Care

Company Income Statement
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Sales 43.71B 42.71B 42.52B 43.82B
Cost of Sales 11.82B 10.42B 9.17B 9.13B
Gross Operating Profit 31.88B 32.29B 33.35B 34.69B
Selling, General, and Administrative Expenses 13.98B 14.12B 13.70B 20.15B
Research & Development 6.47B 6.41B 6.22B 6.88B
Operating Income before D & A (EBITDA) 11.43B 11.76B 13.42B 7.67B
Depreciation & Amortization 2.33B 2.34B 2.21B 2.59B
Interest Income 97.29M 127.66M 139.73M 179.03M
Other Income - Net 3.37B 2.57B 1.84B 898.26M
Special Income / Charges -476.56M 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) 12.16B 12.12B 13.19B 6.16B
Interest Expense 1.20B 1.31B 1.24B 1.28B
Pre-Tax Income 10.96B 10.81B 11.95B 4.87B
Income Taxes 1.68B 3.15B 3.48B 2.01B
Minority Interest 316.61M 289.26M 305.86M 338.00M
Net Income From Continuing Operations 9.28B 7.67B 8.47B 2.86B
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 9.28B 7.67B 8.47B 2.86B
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 8.96B 7.38B 8.17B 2.52B
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
9.76B 7.67B 8.47B 2.86B
Preferred Dividends
Net Income Available To Common 9.28B 7.67B 8.47B 2.86B
Basic EPS from Continuing Ops. 3.71 3.00 3.25 0.99
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 3.71 3.00 3.25 0.99
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 3.71 3.00 3.25 0.99
Basic Normalized Net Income/Share 3.90 3.00 3.25 0.99
EPS fr Continuing Ops. 3.64 2.96 3.19 0.98
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 3.64 2.96 3.19 0.98
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.02 0.00
EPS, Total 3.64 2.96 3.20 0.98
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
3.83 2.96 3.19 0.98
Dividends Paid per Share 2.41 2.48 2.21 2.00
GSK News

GSK GlaxoSmithKline PLC

Analysts Ratings for GSK

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 1 2 2 2
Moderate Buy 0 0 0 0
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 1 0 0 0
GET GSK ANALYST REPORT

Brokerage Partners

GSK Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs